Pfizer entered 2026 in the middle of a strategic transition. Revenue was $62.6 billion in 2025, down from $63.6 billion, yet revenue excluding COVID-19 products grew 6% operationally. The company is simultaneously reducing costs, sharpening R&D priorities, integrating acquired science and building growth platforms intended to offset future losses of exclusivity.
1. Rebuild growth beyond the COVID portfolio
The first strategic priority is to establish a durable post-pandemic growth base. Pfizer’s reported revenue still reflects COVID-product volatility, but management highlighted 6% operational growth in 2025 when COVID products are excluded. That underlying growth is a more useful indicator of whether the non-pandemic portfolio is strengthening.
Pfizer is concentrating commercial resources on key products and geographies rather than treating every asset equally. Eliquis generated about $7.96 billion in 2025 and the Prevnar family about $6.49 billion, showing the importance of maximizing established franchises while newer products scale.
For the economic architecture behind these franchises, see our Pfizer Business Model 2026.
2. Focus R&D on fewer, higher-value opportunities
Pfizer says its R&D pipeline is sharply focused on opportunities where its scientific leadership and capabilities can make the greatest difference. The strategic shift is important: after years of portfolio expansion, productivity depends not simply on the number of programs but on selecting assets with strong scientific rationale, differentiated clinical profiles and meaningful commercial potential.
Pharmaceutical R&D has long development cycles and high failure rates. Concentrating capital on priority programs can improve expected returns, but it also raises the importance of portfolio-selection quality. Pfizer must identify winners early enough to fund them aggressively without allowing organizational scale to preserve weak programs.
These execution risks are assessed in our Pfizer SWOT Analysis 2026.
3. Build a stronger oncology growth platform
The Seagen acquisition materially expanded Pfizer’s oncology capabilities and pipeline. Strategically, oncology offers large unmet needs, multiple biological targets and opportunities for combination therapies, but competition is intense and clinical differentiation is essential.
Pfizer’s opportunity is to combine Seagen’s antibody-drug conjugate expertise with Pfizer’s clinical-development, regulatory, manufacturing and commercial scale. The acquisition only creates value if Pfizer converts that scientific platform into successful launches and indications faster than the cost of capital and future patent losses erode the benefit.
The broader implication is that Pfizer is using M&A not merely to add revenue but to acquire scientific capabilities that can generate multiple assets over time.
4. Use business development to accelerate pipeline renewal
Pfizer continued external innovation in 2025, including the Metsera acquisition and licensing agreements with 3SBio and YaoPharma. This reflects a deliberate strategy to complement internal R&D with external science.
The Metsera transaction gives Pfizer a route into obesity, a large and rapidly evolving therapeutic category. Licensing deals provide another model: Pfizer can access promising assets without always acquiring an entire company. A portfolio of deal structures can improve capital efficiency if milestone payments and economics are matched to scientific risk.
External policy and pricing constraints affecting these investments are analyzed in our Pfizer PESTEL Analysis 2026.
5. Reset the cost base and improve productivity
Pfizer describes 2025 as a year of improved productivity and margins, supported partly by simplifying and streamlining the business. Cost realignment and manufacturing optimization are not separate from growth strategy; they create funding capacity for pipeline investment.
This matters because Pfizer faces a portfolio-renewal challenge. Maintaining an oversized cost structure while mature products decline would compress cash available for R&D and deals. Conversely, cutting too aggressively could damage scientific or commercial capabilities. The strategic objective is therefore productivity rather than indiscriminate cost reduction.
Manufacturing optimization is similarly important. A global pharmaceutical network must balance reliability, regulatory compliance, capacity utilization and cost. Improving that network can raise margins while preserving the supply resilience required for medicines and vaccines.
6. Navigate U.S. pricing policy while protecting innovation economics
Pricing and reimbursement are becoming increasingly important strategic variables. Pfizer reported a voluntary agreement with the U.S. Government in 2025 designed to support lower prescription drug costs and align prices with those in other developed countries, while providing greater clarity and a three-year grace period from certain U.S. tariffs.
The strategic trade-off is clear: Pfizer needs broad patient access and predictable policy while preserving sufficient returns to fund high-risk R&D. Changes in government negotiation, reimbursement or international reference pricing can affect the economics of individual products and therefore the value assigned to pipeline assets.
7. Use AI and digital infrastructure to improve speed
Pfizer is increasing its AI infrastructure and said it plans to expand to more than 1,200 GPUs over two years. The company frames AI, data and adaptability as potential competitive advantages.
The real strategic test is productivity. AI creates value only if it improves decisions or reduces cycle time across discovery, clinical development, manufacturing, medical affairs or commercial operations. Pfizer’s scale provides large datasets and many potential use cases, but also makes integration and organizational adoption critical.
Strategic Outlook
Pfizer’s 2026 strategy is best understood as a simultaneous defense-and-renewal program. The company must maximize current franchises, absorb declining COVID economics, prepare for future patent expirations, lower structural costs and create new growth engines through internal R&D and business development.
The strongest strategic logic is the combination of focus and scale. Pfizer already possesses global development, manufacturing and commercialization capabilities. If it can feed those capabilities with better-selected internal programs and externally sourced science, the same infrastructure can generate greater returns.
The risk is timing. Cost savings can arrive faster than new medicines, while patent expirations can arrive before replacement products reach scale. Pfizer therefore needs both scientific success and execution speed. Its 2025 actions—portfolio sharpening, acquisitions, licensing, cost restructuring and AI investment—show a company trying to shorten that gap and position itself for renewed growth toward the end of the decade.
Source: Pfizer, 2025 Form 10-K.
